ArticleMolecular diagnosis & therapy2026
Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.
Article in Molecular diagnosis & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectiveEarly detection of treatment resistance and progression in metastatic melanoma may improve outcomes, but current surveillance relies on intermittent radiographic imaging that may lag behind dynamic tumor biology. Circulating tumor DNA (ctDNA), a minimally invasive and increasingly validated biomarker, enables real-time disease monitoring. Longitudinal (kinetic) changes in ctDNA over time have been proposed to provide greater insight into disease activity than isolated measurements; however, few studies have evaluated the prognostic significance of longitudinal ctDNA kinetics across extended timepoints. We aimed to assess the relationship between ctDNA concentration, ctDNA longitudinal kinetics, and future radiographic progression in patients receiving systemic therapy.
methodsWe quantified BRAF V600E/V600K, or NRAS Q61 ctDNA using droplet digital polymerase chain reaction from longitudinal plasma samples from patients with metastatic cutaneous melanoma. A multivariate Cox proportional hazards model using a time-to-event framework was fit, treating each patient as contributing multiple 100-day landmark intervals. Predictors of future progression included percent variant allele frequency at each follow-up assessment and Δ% variant allele frequency/month (velocity).
resultsThe model incorporating both single timepoint measures and kinetic ctDNA features achieved strong internal discrimination between progression versus non-progression events within 100 days (100-day time-dependent area under the curve = 0.88) and was used to build a nomogram. Compared with nomogram derived high-risk visits, low-risk visits showed significantly improved progression-free survival (p = 0.00021).
conclusionsUsing a longitudinal time-to-event modeling framework, this proof-of-concept study demonstrates the feasibility of kinetic ctDNA-based risk estimation throughout systemic treatment. Both single-point ctDNA measures and their kinetics may serve as indicators of future disease progression.
Indexed as
Identifiers
41806257What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.